Brought to you by 
BridgeBio raises $299.2mm in late-stage round
29 May 2019
Executive Summary
BridgeBio Pharma raised $299.2mm through a late-stage venture round co-led by existing investors KKR and Viking Global Investors. Returning backers Perceptive Advisors, AIG, Aisling Capital, Cormorant Capital, and Hercules Capital also participated, along with first-time buyers Sequoia Capital and an undisclosed blue-chip long-term investor. BridgeBio is developing treatments for rare genetic diseases and will use the proceeds to support activities related to its pipeline of over 15 candidates in the areas of dermatology, oncology, cardiology, neurology, endocrinology, renal disease, and ophthalmology.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
- Gene Therapy, Cell Therapy
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
BridgeBio raises $299.2mm in late-stage round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice